FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2985666879> ?p ?o ?g. }

• W2985666879 endingPage "9630" @default.
• W2985666879 startingPage "9621" @default.
• W2985666879 abstract "Poor Prognosis With Coexistence Of EGFR T790M Mutation And Common EGFR-Activating Mutation In Non- Small Cell Lung Cancer Xuejuan Gao,1,* Yanfeng Zhao,2,* Yi Bao,2,* Wei Yin,3 Liyu Liu,4 Ruchuan Liu,4 Zhengquan Yu,5 Xiao Zhou,2 Jianwei Shuai1,6 1Department of Physics, Xiamen University, Xiamen, People’s Republic of China; 2Department of Thoracic Surgery, Shanghai Pulmonary Hospital Affiliated to Tongji University, Shanghai, People’s Republic of China; 3Key Laboratory of Oral Biomedical Engineering of Education, Hospital of Stomatology, Wuhan University, Wuhan, People’s Republic of China; 4College of Physics, Chongqing University, Chongqing, People’s Republic of China; 5State Key Laboratories for Agrobiotechnology and Beijing Advanced Innovation Center for Food Nutrition and Human Health, College of Biological Sciences, China Agricultural University, Beijing, People’s Republic of China; 6State Key Laboratory of Cellular Stress Biology, Innovation Center for Cell Signaling Network, Xiamen University, Xiamen, People’s Republic of China*These authors contributed equally to this workCorrespondence: Jianwei ShuaiDepartment of Physics, Xiamen University, Siming South Road 422-19, Xiamen 361005, People’s Republic of ChinaTel +86 13959287814Email jianweishuai@xmu.edu.cnXiao ZhouDepartment of Thoracic Surgery, Shanghai Pulmonary Hospital affiliated to Tongji University, 507 Zhengmin Road, Wu Jiao Chang, Yangpu, Shanghai 200433, People’s Republic of ChinaTel +86 13916118590Email zhouxiaosph@163.comPurpose: Previous studies have shown that the presence of EGFR T790M mutation may reduce the treatment efficacy of tyrosine kinase inhibitors (TKIs) in EGFR-mutant lung cancer. However, little is known about the clinical features and outcomes of EGFR T790M mutation in pretreated patients with NSCLC.Patients and methods: The clinical features of EGFR-activating and T790M mutations were assessed in a large cohort of patients with EGFR-TKI-naïve NSCLC (all/EGFR mutations, n=16,347/7,687). The correlation between the pretreatment T790M mutation status and clinical outcomes was evaluated using univariate and multivariate analyses.Results: Pretreatment T790M mutation was reported in 1.39% of the patients and coexisted with an EGFR-activating or uncommon mutation. The dual EGFR T790M and common EGFR-activating mutations were more likely to be detected in lung adenocarcinoma, whereas single T790M mutation was more prevalent in non-adenocarcinomas. The presence of de novo T790M mutation correlated with reduced recurrence-free survival (RFS) in patients with NSCLC (odds ratio [OR] 3.37, 95% confidence interval [CI] 1.67–6.79, P = 0.001). After molecular stratification, T790M mutation was shown to exert adverse effects on the RFS of EGFR 19-del group (OR 2.89, 95% CI 1.10–7.91, P = 0.028) and EGFR L858R group (OR 3.43, 95% CI 1.33–8.88, P = 0.013). Furthermore, pretreatment T790M mutation promoted tumor metastasis to different sites.Conclusion: T790M-positive tumors presented special clinical features, and the coexistence of T790M and common EGFR-activating mutations was associated with poor prognosis in patients with NSCLC.Keywords: pretreatment T790M mutation, dual EGFR mutations, recurrence-free survival, non-small cell lung cancer" @default.
• W2985666879 created "2019-11-22" @default.
• W2985666879 creator A5014708176 @default.
• W2985666879 creator A5024595141 @default.
• W2985666879 creator A5032336798 @default.
• W2985666879 creator A5034779670 @default.
• W2985666879 creator A5050496811 @default.
• W2985666879 creator A5057964704 @default.
• W2985666879 creator A5069370586 @default.
• W2985666879 creator A5072961920 @default.
• W2985666879 creator A5075266638 @default.
• W2985666879 date "2019-11-01" @default.
• W2985666879 modified "2023-09-28" @default.
• W2985666879 title "<p>Poor Prognosis With Coexistence Of <em>EGFR</em> T790M Mutation And Common <em>EGFR</em>-Activating Mutation In Non- Small Cell Lung Cancer</p>" @default.
• W2985666879 cites W1796195829 @default.
• W2985666879 cites W1905840088 @default.
• W2985666879 cites W1910609151 @default.
• W2985666879 cites W1942770305 @default.
• W2985666879 cites W1944881280 @default.
• W2985666879 cites W1974165720 @default.
• W2985666879 cites W1980497534 @default.
• W2985666879 cites W1988856925 @default.
• W2985666879 cites W2000948841 @default.
• W2985666879 cites W2007118438 @default.
• W2985666879 cites W2014063411 @default.
• W2985666879 cites W2022670843 @default.
• W2985666879 cites W2042331042 @default.
• W2985666879 cites W2043696829 @default.
• W2985666879 cites W2051272460 @default.
• W2985666879 cites W2052705131 @default.
• W2985666879 cites W2060228539 @default.
• W2985666879 cites W2088690976 @default.
• W2985666879 cites W2091421254 @default.
• W2985666879 cites W2095618958 @default.
• W2985666879 cites W2096663872 @default.
• W2985666879 cites W2098395191 @default.
• W2985666879 cites W2132157071 @default.
• W2985666879 cites W2137604100 @default.
• W2985666879 cites W2139804581 @default.
• W2985666879 cites W2154130790 @default.
• W2985666879 cites W2154149901 @default.
• W2985666879 cites W2157824687 @default.
• W2985666879 cites W2159587676 @default.
• W2985666879 cites W2167934111 @default.
• W2985666879 cites W2171139285 @default.
• W2985666879 cites W2234650031 @default.
• W2985666879 cites W2263144737 @default.
• W2985666879 cites W2284844200 @default.
• W2985666879 cites W2594186252 @default.
• W2985666879 cites W2611868247 @default.
• W2985666879 cites W2620500978 @default.
• W2985666879 cites W2745482716 @default.
• W2985666879 cites W2750431888 @default.
• W2985666879 cites W2751696055 @default.
• W2985666879 cites W2790922923 @default.
• W2985666879 cites W2791917433 @default.
• W2985666879 cites W2887139136 @default.
• W2985666879 cites W2889646458 @default.
• W2985666879 cites W2903120675 @default.
• W2985666879 doi "https://doi.org/10.2147/cmar.s216721" @default.
• W2985666879 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6859090" @default.
• W2985666879 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32009817" @default.
• W2985666879 hasPublicationYear "2019" @default.
• W2985666879 type Work @default.
• W2985666879 sameAs 2985666879 @default.
• W2985666879 citedByCount "5" @default.
• W2985666879 countsByYear W29856668792020 @default.
• W2985666879 countsByYear W29856668792021 @default.
• W2985666879 countsByYear W29856668792022 @default.
• W2985666879 crossrefType "journal-article" @default.
• W2985666879 hasAuthorship W2985666879A5014708176 @default.
• W2985666879 hasAuthorship W2985666879A5024595141 @default.
• W2985666879 hasAuthorship W2985666879A5032336798 @default.
• W2985666879 hasAuthorship W2985666879A5034779670 @default.
• W2985666879 hasAuthorship W2985666879A5050496811 @default.
• W2985666879 hasAuthorship W2985666879A5057964704 @default.
• W2985666879 hasAuthorship W2985666879A5069370586 @default.
• W2985666879 hasAuthorship W2985666879A5072961920 @default.
• W2985666879 hasAuthorship W2985666879A5075266638 @default.
• W2985666879 hasBestOaLocation W29856668791 @default.
• W2985666879 hasConcept C104317684 @default.
• W2985666879 hasConcept C121608353 @default.
• W2985666879 hasConcept C126322002 @default.
• W2985666879 hasConcept C143998085 @default.
• W2985666879 hasConcept C166957645 @default.
• W2985666879 hasConcept C191935318 @default.
• W2985666879 hasConcept C205649164 @default.
• W2985666879 hasConcept C2776256026 @default.
• W2985666879 hasConcept C2777930144 @default.
• W2985666879 hasConcept C2778304055 @default.
• W2985666879 hasConcept C2779438470 @default.
• W2985666879 hasConcept C2780580887 @default.
• W2985666879 hasConcept C501734568 @default.
• W2985666879 hasConcept C502942594 @default.
• W2985666879 hasConcept C54355233 @default.
• W2985666879 hasConcept C71924100 @default.
• W2985666879 hasConcept C86803240 @default.
• W2985666879 hasConceptScore W2985666879C104317684 @default.

• next